Tricor 0,145 N30 pills film coated
Condition: New product
1000 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Fenofibrate
Release form
Pills
Composition
Active ingredient: Fenofibrate (Fenofibrate) Concentration of the active substance (mg): 145
Pharmacological effect
Lipid-lowering agent from the group of fibric acid derivatives. lowers blood levels of triglycerides and (to a lesser extent) cholesterol. helps to reduce the content of lopps, lpnp (to a lesser extent), increase the content of anti-atherogenic LPP. mechanism of action is not fully understood. The effect at the Tg level is mainly associated with the activation of the enzyme lipoprotein lipase. Apparently, fenofibrate also disrupts the synthesis of fatty acids; promotes an increase in the number of lpnp receptors in the liver, disrupting cholesterol synthesis. fenofibrate reduces platelet aggregation, reduces elevated levels of fibrinogen in the plasma, can slightly lower the level of glucose in the blood of patients with diabetes mellitus; reduces the level of uric acid in the blood.
Pharmacokinetics
After taking fenofibrate orally, Cmax is reached within 5 hours. When taken 200 mg / day, the average plasma concentration is 15 μg / ml. Css is maintained throughout the treatment period. Plasma protein binding (albumin) is high. In tissues, fenofibrate is converted to the active metabolite - fenofibric acid. Metabolized in the liver. T1 / 2 is 20 hours. It is excreted by the kidneys and through the intestines. Does not cumulate; not displayed during hemodialysis.
Indications
Hyperlipoproteinemia IIa, IIb, III and IV types that are not amenable to diet correction.
Contraindications
Severe abnormal liver and kidney function, pregnancy, lactation (breastfeeding), childish age, hypersensitivity to fenofibrate.
Precautionary measures
Keep out of the reach of children.
Use during pregnancy and lactation
Fenofibrate is contraindicated for use during pregnancy and lactation (breastfeeding).
Dosage and administration
Inside adults - 200-400 mg / day in 3 doses. Preparations containing micronized fenofibrate are prescribed at the rate of 200 mg fenofibrate 1 time / day. Children - 5 mg / kg / day.
Side effects
Possible: dyspeptic phenomena, increased activity of liver enzymes. Rarely: myopathies, increased activity of CPK, skin allergic reactions.
Overdose
Cases of overdose are not described. The specific antidote is unknown. If overdose is suspected, symptomatic and, if necessary, supportive treatment should be prescribed. Hemodialysis is ineffective.
Interaction with other drugs
With simultaneous use with hypoglycemic agents of sulfonylurea there are reports of increased hypoglycemic action. With the simultaneous use of indirect anticoagulants (including acenocoumarol, warfarin) their effects are enhanced. Fibrates are believed to increase the affinity of anticoagulants for the corresponding receptors or, possibly, disrupt their metabolism. If used concurrently with cyclosporine, kidney function may deteriorate and plasma cyclosporin levels may increase.
special instructions
In the process of treatment with fenofibrate, systematic monitoring of the level of hepatic transaminases and blood coagulation parameters are necessary.